Rosuvastatin for the treatment of patients with hypercholesterolemia

Annals of Pharmacotherapy

Volumn 36, Issue 1, 2002, Pages 93-101

  Chong, Pang H ^a,b,c   Yim, Barbara T ^a  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

HMG CoA reductase inhibitor; Rosuvastatin calcium; ZD5422

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BIBLIOGRAPHIC DATABASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; PYRIMIDINES; SULFONAMIDES;

EID: 0036142105     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A033     Document Type: Review

References (51)

1. Cholesterol reduction yields clinical benefit: Impact of statin trials
2. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
3. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
4. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
5. Incidence of coronary disease and lipoprotein cholesterol levels. The Framingham Study
6. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment changes in risk factors and incidence of coronary heart disease
7. Gemfibrozil for the secondary prevention of heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
10. Recommendations for the management and treatment of dyslipidemia
11. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
12. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
13. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study
15. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
16. The effect of aggressive lowering of low-density lipoprotein cholesterol levels, and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
17. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
18. Results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
19. Novel approaches to lipid lowering: What is on the horizon?
20. The aggressive low density lipoprotein lowering controversy
21. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
22. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
23. ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines
24. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
25. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
26. ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia
27. Effects of NK-104, a new hydroxymethyl-glutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
28. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3.5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors
29. A receptor-mediated pathway for cholesterol homeostasis
30. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat (abstract MoP21:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000
31. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells (abstract MoP29:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000
32. Pharmacological properties of ZD4522, a new HMG-CoA reductase inhibitor (abstract MoP20:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000
33. New HMG-CoA reductase inhibitor ZD4522 lowers plasma lipids and VLDL production in APOE*3 Leiden transgenic mice (abstract WeP1:W17). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000
34. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 (abstract MoP19:W6). XIIth International Symposium on Atherosclerosis. Stockholm, June 25-29, 2000
35. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects (abstract 48). 29th Annual Meeting of the American College of Clinical Pharmacology, Chicago, September 17-19, 2000
36. Pharmacologic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after AM and PM administration in healthy subjects (abstract 47). 29th Annual Meeting of the American College of Clinical Pharmacology, Chicago, September 17-19, 2000
37. ZD4522 - An HMG-CoA reductase inhibitor free metabolically mediated drug interactions: Metabolic studies in human in vitro systems
38. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
39. Development of taxyphylaxis among patients taking HMG CoA reductase inhibitors
40. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients
41. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolemia: The pivotal placebo-controlled clinical trial
42. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis
43. Effects of treatment with the statin, ZD4522, on peripheral nerve function and perfusion in diabetic rats
44. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid
45. Safety profiles for the HMG-CoA reductase inhibitors